An Open-label Extension Study to Evaluate the Long Term Safety, Tolerability, Efficacy and Pharmacokinetics of CDZ173 in Patients With APDS/PASLI (Activated Phosphoinositide 3-kinase Delta Syndrome/p110δ-activating Mutation Causing Senescent T Cells, Lymphadenopathy and Immunodeficiency)

Trial Profile

An Open-label Extension Study to Evaluate the Long Term Safety, Tolerability, Efficacy and Pharmacokinetics of CDZ173 in Patients With APDS/PASLI (Activated Phosphoinositide 3-kinase Delta Syndrome/p110δ-activating Mutation Causing Senescent T Cells, Lymphadenopathy and Immunodeficiency)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 03 May 2017

At a glance

  • Drugs CDZ 173 (Primary)
  • Indications Immunodeficiency disorders
  • Focus Adverse reactions; Registrational
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 22 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 12 Aug 2016 New trial record
    • 09 Aug 2016 Planned End Date changed from 1 Jan 2020 to 1 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top